Representation and inclusion in clinical trials
Paving the way for inclusive clinical trials: establishing a platform for improvement
Advancements in AI for site selection
Learn how ICON is using human-enabled AI to efficiently integrate, interrogate and interpret large datasets from multiple sources and gain valuable insights for site selection in both expected and unexpected ways.
Equity and inclusion in rare disease clinical trials: beyond buzzwords
The rarity of each individual rare disease introduces many unique challenges and complexity in clinical research including barriers to achieving representative trial populations and equitable access to trials.
.png?crop=yes&w=982&h=600&a=938,0&itok=r0pMiSn- "11828-005-Front-Page-Banner_Subpage-banner_1-(1)"){kind=icon}
Inclusion in clinical trials whitepaper
Examining how the field of clinical research currently approaches inclusive enrolment gives us a baseline understanding on which we can build and make the necessary changes for improvement in the future. ICON looked at the barriers to accessing under-represented subgroups, the regulatory landscape and how organisations are addressing this issue and brings together the findings in this Whitepaper.
The promise of decentralised models and inclusion in clinical trials
ICON invited senior executives from Amgen, Sanofi, Eli Lilly and Janssen Research & Development LLC to discuss how decentralised and hybrid clinical trial models can provide increased resilience and how their respective organisations currently (or are likely to) address representation and inclusion in clinical trials into the future.
Representative clinical trials in a post-pandemic world
Inclusive clinical research has been a major topic of discussion for years, but it took the COVID-19 pandemic for the biopharma industry to fully realise the importance of recruiting representative populations into studies.
-
Media article: Regulatory considerations in technology for decentralised clinical trials
This article in the Journal of mHealth explores the guidance regulators have provided for diversity and inclusion in clinical trials, privacy considerations and endpoint selection.
-
.jpg?crop=yes&w=545&h=286&itok=xtR9s0RK "Female Leadership (5)")
Media article: Endpoints News LGBTQ+ Biopharma Leaders '23
This report profiles a group of scientists, executives, founders and academics who are leading the way for LGBTQ+ inclusion in the drug development industry.
-
.jpg?crop=yes&w=545&h=286&itok=DPnprpn- "iStock-1164377567 (4)")
Media article: Equipping our people leaders to drive an inclusive organisation
Mary O’Reilly and Nikki O’Hanlon discuss the vital role that people leaders play in driving diversity and inclusion within an organisation.
-
Media article: Black History Month 2022
These series focus on past motivations, overcoming hurdles, helpful resources and other topics regarding activities during Black History Month.
-
Blog: How we can continue building a diverse, equal, and inclusive industry
Workplace diversity encourages collaboration and innovation – every team member brings their own unique backgrounds, experiences, and perspectives at ICON.
-
Media article: Diversity and inclusion in clinical trials
The inclusion of diverse patient populations in clinical trials is nothing new but the topic has risen to the surface in the last year and is now prevalent in high profile conferences and industry exchange.
-
Media article: Trailblazing women stress importance of diversity in pharma
There has been a failure to attract enough girls to doing science, technology, engineering and mathematics (STEM) subjects in secondary school and in college.
-
Media article: The pursuit of patient diversity in clinical trials
Everyone knows that increasing the diversity of clinical trial populations is a top priority for global pharma.
.jpg?crop=yes&w=2048&h=1077&a=0,145&itok=btAB-dr8 "Female Leadership (5)"){kind=icon}
.jpg?crop=yes&w=2048&h=1077&a=0,145&itok=u1KY_diz "iStock-1164377567 (4)"){kind=icon}
